학술논문
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: Rationale, methods, and trial design
Document Type
Article
Author
Source
In: International Journal of Gynecological Cancer . (International Journal of Gynecological Cancer, 2024)
Subject
Language
English
ISSN
15251438
1048891X
1048891X